Analyst Price Targets — CLYM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 24, 2026 10:03 am | — | H.C. Wainwright | $24.00 | $17.28 | TheFly | Climb Bio price target raised to $24 from $20 at H.C. Wainwright |
| August 7, 2026 2:07 pm | — | Truist Financial | $25.00 | $13.90 | TheFly | Climb Bio price target raised to $25 from $17 at Truist |
| August 3, 2026 10:07 am | Nevin Varghese | RBC Capital | $23.00 | $11.90 | TheFly | Climb Bio initiated with an Outperform at RBC Capital |
| June 11, 2026 4:20 pm | Julian Harrison | BTIG | $20.00 | $11.17 | TheFly | Climb Bio price target raised to $20 from $19 at BTIG |
| June 8, 2026 11:13 am | — | Guggenheim | $35.00 | $10.55 | TheFly | Climb Bio initiated with a Buy at Guggenheim |
| May 12, 2026 10:13 am | Raghuram Selvaraju | H.C. Wainwright | $20.00 | $11.12 | TheFly | Climb Bio price target raised to $20 from $15 at H.C. Wainwright |
| May 8, 2026 1:39 pm | — | Wedbush | $17.00 | $12.06 | TheFly | Climb Bio price target raised to $17 from $15 at Wedbush |
| May 6, 2026 10:44 am | — | Robert W. Baird | $21.00 | $11.45 | TheFly | Climb Bio price target raised to $21 from $12 at Baird |
| May 5, 2026 8:02 am | — | Chardan Capital | $22.00 | $9.69 | TheFly | Climb Bio initiated with a Buy at Chardan |
| April 15, 2026 8:47 am | Joseph Catanzaro | Mizuho Securities | $18.00 | $8.85 | TheFly | Climb Bio initiated with an Outperform at Mizuho |
Latest News for CLYM
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.25 and last traded at $14.24. Approximately 228,260 shares changed hands during trading, a
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.42 and last traded at $12.79, with a
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLYM.
U.S. House Trading
No House trades found for CLYM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.